Bennett RL - Search Results

1

Espinoza Pereira KN, Shan J, Licht JD, Bennett RL. Espinoza Pereira KN, et al. Among authors: bennett rl. Biochem Soc Trans. 2023 Oct 31;51(5):1749-1763. doi: 10.1042/BST20210567. Biochem Soc Trans. 2023. PMID: 37721138 Free PMC article.

2

Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.

Mahajan N, Wu HJ, Bennett RL, Troche C, Licht JD, Weber JD, Maggi LB Jr, Tomasson MH. Mahajan N, et al. Among authors: bennett rl. FASEB J. 2017 Feb;31(2):482-490. doi: 10.1096/fj.201600654R. Epub 2016 Oct 24. FASEB J. 2017. PMID: 28148777 Free PMC article.

3

The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Bennett RL, Swaroop A, Troche C, Licht JD. Bennett RL, et al. Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):a026708. doi: 10.1101/cshperspect.a026708. Cold Spring Harb Perspect Med. 2017. PMID: 28193767 Free PMC article. Review.

4

Targeting Epigenetics in Cancer.

Bennett RL, Licht JD. Bennett RL, et al. Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:187-207. doi: 10.1146/annurev-pharmtox-010716-105106. Epub 2017 Oct 6. Annu Rev Pharmacol Toxicol. 2018. PMID: 28992434 Free PMC article. Review.

5

An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.

Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, Bulic M, Durham BH, Wen QJ, Crispino JD, MacKerell AD Jr, Bennett RL, Kelleher NL, Licht JD. Swaroop A, et al. Among authors: bennett rl. Oncogene. 2019 Jan;38(5):671-686. doi: 10.1038/s41388-018-0474-y. Epub 2018 Aug 31. Oncogene. 2019. PMID: 30171259 Free PMC article.

6

Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.

Huang X, LeDuc RD, Fornelli L, Schunter AJ, Bennett RL, Kelleher NL, Licht JD. Huang X, et al. Among authors: bennett rl. J Biol Chem. 2019 Aug 16;294(33):12459-12471. doi: 10.1074/jbc.RA118.006159. Epub 2019 Jun 27. J Biol Chem. 2019. PMID: 31248990 Free PMC article.

7

A Mutation in Histone H2B Represents a New Class of Oncogenic Driver.

Bennett RL, Bele A, Small EC, Will CM, Nabet B, Oyer JA, Huang X, Ghosh RP, Grzybowski AT, Yu T, Zhang Q, Riva A, Lele TP, Schatz GC, Kelleher NL, Ruthenburg AJ, Liphardt J, Licht JD. Bennett RL, et al. Cancer Discov. 2019 Oct;9(10):1438-1451. doi: 10.1158/2159-8290.CD-19-0393. Epub 2019 Jul 23. Cancer Discov. 2019. PMID: 31337617 Free PMC article.

8

Targeting epigenetic mechanisms to overcome venetoclax resistance.

Prado G, Kaestner CL, Licht JD, Bennett RL. Prado G, et al. Among authors: bennett rl. Biochim Biophys Acta Mol Cell Res. 2021 Jul;1868(8):119047. doi: 10.1016/j.bbamcr.2021.119047. Epub 2021 May 1. Biochim Biophys Acta Mol Cell Res. 2021. PMID: 33945824 Free PMC article. Review.

9

Leveraging epigenetics to enhance the efficacy of immunotherapy.

Licht JD, Bennett RL. Licht JD, et al. Among authors: bennett rl. Clin Epigenetics. 2021 May 17;13(1):115. doi: 10.1186/s13148-021-01100-x. Clin Epigenetics. 2021. PMID: 34001289 Free PMC article. Review.

10

PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.

Li J, Hlavka-Zhang J, Shrimp JH, Piper C, Dupéré-Richér D, Roth JS, Jing D, Casellas Román HL, Troche C, Swaroop A, Kulis M, Oyer JA, Will CM, Shen M, Riva A, Bennett RL, Ferrando AA, Hall MD, Lock RB, Licht JD. Li J, et al. Among authors: bennett rl. Cancer Discov. 2022 Jan;12(1):186-203. doi: 10.1158/2159-8290.CD-20-1771. Epub 2021 Aug 20. Cancer Discov. 2022. PMID: 34417224

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

224 results

Search Page

Filters